Epigenetics is the study of heritable changes in gene expression that occur without altering the DNA sequence. These changes regulate whether genes are turned on or off. In cancer, abnormal epigenetic modifications can silence tumor suppressor genes or activate cancer-promoting genes, contributing to tumor initiation, progression, and resistance to therapy.
1. DNA Methylation DNA methylation involves the addition of a methyl group (CH₃) to cytosine bases, usually at CpG islands in gene promoter regions. Normal Function Regulates normal gene expression. Maintains genomic stability. Controls embryonic development and cell differentiation.
In Cancer Hypermethylation of tumor suppressor gene promoters silences genes that normally prevent cancer. Hypomethylation can activate oncogenes and increase genomic instability. Examples Methylation of genes such as CDKN2A (p16), MLH1, and BRCA1 contributes to several cancers.
2. Histone Modifications DNA is wrapped around histone proteins to form chromatin. Chemical modifications of histones determine whether DNA is accessible for transcription. Common modifications include: Histone acetylation Histone deacetylation Histone methylation Histone phosphorylation Histone ubiquitination Normal Function Controls chromatin structure. Regulates gene expression In Cancer Loss of histone acetylation often suppresses tumor suppressor genes. Abnormal histone methylation patterns promote uncontrolled cell growth.
3. Non-Coding RNAs (ncRNAs) Non-coding RNAs regulate gene expression without producing proteins. MicroRNAs (miRNAs) Small RNAs (approximately 22 nucleotides) that bind messenger RNA (mRNA) and inhibit protein production. Role in Cancer Some miRNAs function as tumor suppressors. Others function as oncogenes (oncomiRs Long Non-Coding RNAs (lncRNAs) RNAs longer than 200 nucleotides that regulate transcription and chromatin organization. Role in Cancer Influence tumor growth. Promote invasion and metastasis. Affect response to treatment. How Epigenetic Changes Contribute to Cancer Abnormal epigenetic regulation can lead to: Silencing of tumor suppressor genes Activation of oncogenes Increased cell proliferation Reduced apoptosis (programmed cell death) Enhanced angiogenesis Increased invasion and metastasis Drug resistance Immune evasion Epigenetic Biomarkers Epigenetic alterations are useful as biomarkers because they often occur early during cancer development. Applications include: Early cancer detection Cancer diagnosis Prognosis Prediction of treatment response Monitoring disease recurrence Examples include methylated DNA detected in blood, urine, or other body fluids through liquid biopsy. Epigenetic Therapy Unlike DNA mutations, many epigenetic changes are reversible, making them attractive therapeutic targets. Current classes of epigenetic drugs include: DNA Methyltransferase (DNMT) Inhibitors These drugs reduce abnormal DNA methylation and reactivate silenced tumor suppressor genes. Examples: Azacitidine Decitabine Used mainly for: Myelodysplastic syndromes Acute myeloid leukemia Histone Deacetylase (HDAC) Inhibitors These drugs increase histone acetylation, restoring expression of genes that suppress tumor growth. Examples: Vorinostat Romidepsin Belinostat Used for selected hematologic malignancies such as certain lymphomas. Clinical Applications Epigenetics is increasingly integrated into precision oncology through: Identification of cancer-specific methylation signatures Patient stratification for targeted therapies Monitoring minimal residual disease Combination therapies with chemotherapy, immunotherapy, and targeted therapy Development of personalized treatment strategies Advantages of Epigenetic Biomarkers Detectable at early stages of cancer Non-invasive testing through liquid biopsy Potentially reversible abnormalities Useful for prognosis and treatment monitoring Applicable across multiple cancer types Summary Epigenetics refers to changes in gene expression without changes to the DNA sequence. In cancer, abnormal DNA methylation, histone modifications, and non-coding RNA regulation disrupt normal cellular control, leading to uncontrolled growth, metastasis, and treatment resistance. Because these changes are often reversible, epigenetic biomarkers and therapies have become an important component of modern precision oncology, improving cancer diagnosis, prognosis, and personalized treatment.
